Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Gw Pharma ADR (NQ: GWPH )

153.93 USD +3.70 (+2.46%)
Streaming Delayed Price Updated: 9:56 AM EST, Jan 27, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Gw Pharma ADR

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy
From GlobeNewswire News Releases
GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug
From GlobeNewswire News Releases
GW Pharmaceuticals to Host Virtual Investor Event on Its Nabiximols U.S. Development Program and Market Opportunity
From GlobeNewswire News Releases
GW Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
From GlobeNewswire News Releases
GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress
From GlobeNewswire News Releases
GW Pharmaceuticals to Present at the Bank of America Healthcare Conference 2020
From GlobeNewswire News Releases
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the First Quarter Ending March 31st, 2020 and Host Conference Call on May 11th, 2020
From GlobeNewswire News Releases
Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors
From GlobeNewswire News Releases
GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance
From GlobeNewswire News Releases
GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Co
PDUFA date of July 31, 2020 
From GlobeNewswire News Releases
GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated w
From GlobeNewswire News Releases
JAMA Neurology Publishes Results from Positive Phase 3 Trial of EPIDIOLEX® (cannabidiol) oral solution in Children with Seizures Associated with Dravet Syndrome
EPIDIOLEX significantly reduced convulsive seizure frequency in children taking multiple anti-epileptic drugs with poor seizure control 
From GlobeNewswire News Releases
CBD Companies Just Starting to See Big Opportunity Emerge in Europe
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
CBD Companies Just Starting to See Big Opportunity Emerge in Europe
Financialnewsmedia.com News Commentary 
From PR Newswire
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress
From GlobeNewswire News Releases
Monumental Demand: CBD Market on Course to Grow 400% in Europe Alone
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Monumental Demand: CBD Market on Course to Grow 400% in Europe Alone
Financialnewsmedia.com News Commentary 
From PR Newswire
GW Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference
From GlobeNewswire News Releases
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Fourth Quarter and Year Ending December 31, 2019 and Host Conference Call on February 25th, 2020
From GlobeNewswire News Releases
Thinking about trading options or stock in Amazon.com, Beyond Meat, FedEx, GW Pharmaceuticals, or T-Mobile?
InvestorsObserver issues critical PriceWatch Alerts for AMZN, BYND, FDX, GWPH, and TMUS. 
From PR Newswire
GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex® (cannabidiol) for the Treatment of Tuberous Sclerosis Complex
From GlobeNewswire News Releases
GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales
From GlobeNewswire News Releases
GW Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Greenwich Biosciences, a GW Pharmaceuticals Company, Presents New Data for EPIDIOLEX® (cannabidiol) in Patients with Tuberous Sclerosis Complex (TSC) at the American Epilepsy Society Annual Meeting
Study results showed EPIDIOLEX significantly reduced difficult-to-treat seizures associated with TSC and improved overall patient condition as reported by caregivers 
From GlobeNewswire News Releases
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting
Meeting Highlights Include New Phase 3 Data for EPIDIOLEX in Tuberous Sclerosis Complex and Award-Winning Virtual Reality Experience 
From GlobeNewswire News Releases
Medical Cannabis Industry Market Report 2019: Market Share, Size, Growth, Trends, Forecast and Analysis of Key players 2024
Tags Pharmaceuticals & Biotech Health & Medicine World
From AB Newswire
GW Pharmaceuticals to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
GW Pharmaceuticals receives positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
From GlobeNewswire News Releases
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019
From GlobeNewswire News Releases
GW Pharmaceuticals to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.